Insulet - PODD Stock Forecast, Price & News

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Price Performance

Shares of Insulet stock opened at $270.70 on Friday. The company has a debt-to-equity ratio of 3.28, a current ratio of 4.69 and a quick ratio of 4.51. The business's 50 day simple moving average is $231.79 and its two-hundred day simple moving average is $237.38. The stock has a market capitalization of $18.79 billion, a P/E ratio of 541.40 and a beta of 0.73. Insulet has a one year low of $181.00 and a one year high of $324.81.

Insulet (NASDAQ:PODD - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of $0.22 by ($0.72). The company had revenue of $299.40 million during the quarter, compared to analysts' expectations of $290.87 million. Insulet had a return on equity of 13.83% and a net margin of 2.94%. Insulet's revenue for the quarter was up 13.8% on a year-over-year basis. During the same period last year, the firm earned $0.10 earnings per share. Analysts forecast that Insulet will post 0.87 EPS for the current year.

Analysts Set New Price Targets

PODD has been the topic of several recent analyst reports. Canaccord Genuity Group raised their price target on Insulet from $250.00 to $290.00 and gave the company a "buy" rating in a report on Friday, August 5th. BTIG Research raised their price target on Insulet to $285.00 in a report on Tuesday, August 9th. Wells Fargo & Company lowered their price target on Insulet from $357.00 to $345.00 in a report on Friday, May 6th. Morgan Stanley raised their price target on Insulet from $244.00 to $273.00 and gave the company an "equal weight" rating in a report on Monday, August 8th. Finally, Piper Sandler raised their price target on Insulet from $230.00 to $235.00 and gave the company a "neutral" rating in a report on Friday, August 5th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $295.23.

Insiders Place Their Bets

In other Insulet news, COO Charles Alpuche sold 6,000 shares of Insulet stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $215.32, for a total value of $1,291,920.00. Following the transaction, the chief operating officer now directly owns 43,899 shares of the company's stock, valued at approximately $9,452,332.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Charles Alpuche sold 6,000 shares of Insulet stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $215.32, for a total value of $1,291,920.00. Following the sale, the chief operating officer now directly owns 43,899 shares in the company, valued at approximately $9,452,332.68. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $222.90, for a total value of $3,343,500.00. Following the completion of the sale, the director now owns 13,695 shares in the company, valued at $3,052,615.50. The disclosure for this sale can be found here. Insiders own 0.90% of the company's stock.